(Q49501208)

20 February 2018

http://europepmc.org/abstract/MED/28988363

title

Safety of shortened infusion times for combined ipilimumab and nivolumab (English)

1 reference

20 February 2018

http://europepmc.org/abstract/MED/28988363

author

Nikolaus B Wagner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Claus Garbe

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Maximilian Gassenmaier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alexander Scheu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lukas Kofler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alisa Mueller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Dennis Doecker

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Thomas Kurt Eigentler

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Andrea Forschner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Hans-Peter Lipp

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

7 October 2017

1 reference

20 February 2018

http://europepmc.org/abstract/MED/28988363

published in

Cancer Immunology, Immunotherapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

135-140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Safety of Infusing Ipilimumab Over 30 Minutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Rapid infusion rituximab for maintenance therapy: is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Adverse side-effects to biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-017-2075-Y

10.1007/S00262-017-2075-Y

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988363%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

1092125353

0 references

Fatcat ID

release_b44vgd5xyfepdomtcemq5xjcna

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b44vgd5xyfepdomtcemq5xjcna

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference